“It is better to have a short life that is full of what you like doing than a long life spent in a miserable way.”
— Alan Watts
Governed Biotech
Intelligence
We don’t create complexity. We reveal clarity.
The Moment
The gap between the headliner and the “never-was” is razor thin. Most people treat the PDUFA date as the defining moment in a brand’s life. An earlier one matters just as much: the trial submission window.
History remembers the breakthroughs. It forgets the launches that quietly miss. Many of those failures weren’t scientific. They were operational: over 75% of trial protocols need a substantial amendment after filing1, and one in four Phase 2–3 procedures supports a non-core endpoint1. The signal was there. Someone just didn’t see it in time.
Solvynt finds that signal before it’s lost in the noise.
Getting that window right isn’t just an advantage.
It’s the price of admission to tomorrow.
Philosophy
Speed without governance is exposure, not advantage.
Confirmation bias doesn’t need speed. It needs a way in.
We took a different approach to AI: built to break bias, not confirm it, surfacing untapped market potential in the process.
We aren’t in the pattern recognition game.
We are governed conviction.
People
60+ years combined experience across strategy, media, technology, and finance. The real asset, though, is what that diversity affords us.
We see the whole field before we ever step onto it. Separate backgrounds provide a genuine range of ways to approach a challenge, sharpened by people wired differently from the start.
Earned in the trenches, as friends. That kind of history buys you something most teams never get: the standing to disagree, hard, and still be heard without breaking under pressure. It’s been tested for decades, long before there was a company riding on it.
